Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The threshold-suspend feature of sensor-augmented insulin pumps is designed to minimize the risk of hypoglycemia by interrupting insulin delivery at a preset sensor glucose value. We evaluated sensor-augmented insulin-pump therapy with and without the threshold-suspend feature in patients with nocturnal hypoglycemia. METHODS: We randomly assigned patients with type 1 diabetes and documented nocturnal hypoglycemia to receive sensor-augmented insulin-pump therapy with or without the threshold-suspend feature for 3 months. The primary safety outcome was the change in the glycated hemoglobin level. The primary efficacy outcome was the area under the curve (AUC) for nocturnal hypoglycemic events. Two-hour threshold-suspend events were analyzed with respect to subsequent sensor glucose values. RESULTS: A total of 247 patients were randomly assigned to receive sensor-augmented insulin-pump therapy with the threshold-suspend feature (threshold-suspend group, 121 patients) or standard sensor-augmented insulin-pump therapy (control group, 126 patients). The changes in glycated hemoglobin values were similar in the two groups. The mean AUC for nocturnal hypoglycemic events was 37.5% lower in the threshold-suspend group than in the control group (980 ± 1200 mg per deciliter [54.4 ± 66.6 mmol per liter] × minutes vs. 1568 ± 1995 mg per deciliter [87.0 ± 110.7 mmol per liter] × minutes, P<0.001). Nocturnal hypoglycemic events occurred 31.8% less frequently in the threshold-suspend group than in the control group (1.5 ± 1.0 vs. 2.2 ± 1.3 per patient-week, P<0.001). The percentages of nocturnal sensor glucose values of less than 50 mg per deciliter (2.8 mmol per liter), 50 to less than 60 mg per deciliter (3.3 mmol per liter), and 60 to less than 70 mg per deciliter (3.9 mmol per liter) were significantly reduced in the threshold-suspend group (P<0.001 for each range). After 1438 instances at night in which the pump was stopped for 2 hours, the mean sensor glucose value was 92.6 ± 40.7 mg per deciliter (5.1 ± 2.3 mmol per liter). Four patients (all in the control group) had a severe hypoglycemic event; no patients had diabetic ketoacidosis. CONCLUSIONS: This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced nocturnal hypoglycemia, without increasing glycated hemoglobin values. (Funded by Medtronic MiniMed; ASPIRE ClinicalTrials.gov number, NCT01497938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“People with diabetes who continue to have frequent and severe hypoglycemia and/or impaired awareness of hypoglycemia, despite educational interventions, may benefit from continuous subcutaneous insulin infusion (CSII) therapy or continuous glucose monitoring (CGM) or both (i.e. a sensor augmented pump), to reduce the risk of severe hypoglycemia (44)(45)(46)(47).”
From Hypoglycemia (2018) · cites this paper as [46]
In the citing paper
“Insulin pumps with automated low-glucose suspend and automated insulin delivery systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (126).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [126]
In the citing paper
“Reduction of nocturnal hypoglycemia in individuals with type 1 diabetes using insulin pumps with CGM is improved by automatic suspension of insulin delivery at a preset glucose level, with further improvements when using devices with predictive low-glucose insulin delivery suspension (24,25).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [24]
In the citing paper
“CGM with automated low glucose suspend and hybrid closed-loop systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (95).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [95]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Self-citationHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Fear of hypoglycemia: quantification, validation, and utilization
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, J. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.617 · Cited by 579
Mechanisms of Hypoglycemia-Associated Autonomic Failure and Its Component Syndromes in Diabetes
Cryer, P. E. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3592 · Cited by 401
Adaptive increase in sample size when interim results are promising: a practical guide with examples
Mehta, C. R., & Pocock, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4102 · Cited by 367
Towler, D. A., Havlin, C. E., Craft, S., & Cryer, P. (1993) · Diabetes · doi:10.2337/diab.42.12.1791 · Cited by 258
Tanenberg, R. J., Newton, C. A., & Drake, A. J. (2010) · Endocrine Practice · doi:10.4158/ep09260.cr · Cited by 225
Increasing the sample size when the unblinded interim result is promising
Chen, Y. H. J., DeMets, D. L., & Gordon Lan, K. K. (2004) · Statistics in Medicine · doi:10.1002/sim.1688 · Cited by 207
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Cited by
Items 501–600 of 662
Pathophysiology and Management of Type 1 Diabetes
Georga, E. I., Fotiadis, D. I., & Tigas, S. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804831-3.00002-9 · Cited by 4
S2e-Leitlinie Diabetes und Straßenverkehr: 1. Auflage 2017– AWMF-Register-Nr. 057-026
(DDG), D. D. G., Ebert, O., Bohn, B., Bertram, B., Buchberger, B., Finck, H., Hoß, J., Hubner, P. J. B., Krabbe, L. M., Kulzer, B., et al. (2018) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-124953 · Cited by 2
Paglialunga, S., Morimoto, B. H., de la Peña, A., & Fortier, C. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.437 · Cited by 2
L’internista ospedaliero nella gestione del paziente diabetico complesso
Magnani, G. E. L., Beltramello, G., Brancato, D., Fontanella, A., & Nardi, R. (2018) · Italian Journal of Medicine · doi:10.4081/itjm.q.2018.2 · Cited by 2
Hypoglycemia: Diagnosis, Management, and Prevention
Faradji, R. N., Uribe-Wiechers, A. C., & Viadero, M. E. S. D. L. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_42 · Cited by 2
Advances in Exercise, Physical Activity, and Diabetes Mellitus
Mohajeri, S., & Riddell, M. C. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.1511 · Cited by 2
Insulin delivery devices for diabetes mellitus from open-loop to closed-loop
Lian, D. (2021) · AIP conference proceedings · doi:10.1063/5.0049209 · Cited by 2
Islet Cell or Pancreas Transplantation
Piemonti, L., Socci, C., Nano, R., Maffi, P., & Secchi, A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_23-1 · Cited by 2
Rousset, M. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(15)30188-9 · Cited by 2
“47mg/dL/min dans l’étude ASPIRE [15]).”
Little, S. A., Leelarathna, L., Walkinshaw, E., Tan, H. K., Chapple, O., Lubina-Solomon, A., Chadwick, T. J., Barendse, S., Stocken, D. D., Brennand, C., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1947 · Cited by 2
Insulin Management in Type 1 Diabetes
Crasto, W., Jarvis, J., & Davies, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-10939-8_5 · Cited by 1
Therapy of Type 1 Diabetes Mellitus
Omura, E., Cohan, P., & Peters, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_43-2 · Cited by 1
L’insulinothérapie dans le diabète de type 1 : un paysage en constante évolution
Renard, É. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.12.001 · Cited by 1
Hypoglycemia: Diagnosis, Management, and Prevention
Faradji, R. N., Uribe-Wiechers, A. C., & de la Maza, E. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_45 · Cited by 2
2023 Clinical Practice Guidelines for Diabetes: Continuous Glucose Monitoring and Insulin Pumps
Jin, S. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.3.141 · Cited by 1
“그러나 연속혈당측정 기기의 상시적 사용에도 불구 하고 여전히 저혈당 위험이 높은 1형당뇨병 성인에게서는 연 속혈당측정센서와 연동되어 일정한 한도 아래로 혈당이 낮 아지거나(low glucose suspend, LGS), 30분 후 낮아질 것 으로 예측하는 경우 인슐린주입을 멈추는(predictive LGS, PLGS) 알고리듬이 적용된 형태의 센서강화인슐린펌프를 사 용하는 것이 저혈당 위험을 더욱 감소시킬 수 있음이 알려져 있다[8,29,30].”
Anne, B., Kauloorkar, B., Kunnuru, S. R., Thomas, G., Divyasri, N., & b., S. G. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1177/29986702251394387 · Cited by 1
“10 Although Group B (CSII) had a higher average TAR, the difference was borderline signi fi cant ( P = 0.0522), and fewer patients in both groups achieved the recommended targets for TIR and TAR.”
InfluentialKublin, O., Filipowicz, D., Kublin, M., Ruchała, M., & Stȩpień, M. (2026) · Clinical Diabetology · doi:10.5603/cd.109914 · Cited by 1
mHealth Environments for Chronic Disease Management
Georga, E. I., Papadopoulos, A. N., & Fotiadis, D. I. (2015) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-4666-8828-5.ch024 · Cited by 2
Hypoglykämie bei Kindern und Jugendlichen
Schwab, K. O., & Doerfer, J. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-57309-9_13 · Cited by 1
Automatic insulin-pump suspension reduces hypoglycaemia
Kugelberg, E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.143 · Cited by 1
Auf dem Weg zum „Closed-loop“-System: Bestandteile und Schritte
Thomas, A., Heinemann, L., & Freckmann, G. (2014) · Der Diabetologe · doi:10.1007/s11428-013-1127-y · Cited by 1
Golukhova, E. Z., Магомедова, Н. М., & Chebotareva, G. E. (2016) · Diabetes Mellitus · doi:10.14341/dm7710 · Cited by 1
“Непрерывный мониторинг глюкозы статистически значимо снижает уровень гликированного гемоглобина (HbA1c) и вариабельность изменений глюкозы по сравнению с применением только самостоятельного мониторинга уровня глюкозы крови [9], обеспечивает улучшение гликемического профиля.”
InfluentialThuillier, P., Sonnet, E., Roudaut, N., Hervé, D., & Kerlan, V. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.02.003 · Cited by 1
Future Drug Treatments for Type 1 Diabetes
Sherr, J. L., Cengiz, E., Name, M. A. V., WEINZIMER, S. A., & Tamborlane, W. V. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch66 · Cited by 1
Cryer, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00034-4 · Cited by 5
Paediatric type 1 diabetes 2018: Clinical and research insights
Zborovski, S., & Mahmud, F. H. (2018) · Paediatrics & Child Health · doi:10.1093/pch/pxx214 · Cited by 2
Hautier-Suply, O., Friedmann, Y., & Shapley, J. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.1.30 · Cited by 1
Relevancia del monitoreo continuo de glucosa en la práctica clínica: revisión de la evidencia
Gómez, A. M., Carrillo, D. C. H., Tapoada, L., & Toro, M. R. (2018) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.5.3.432 · Cited by 3
“El estudio ASPIRE demostró una reducción de área bajo la curva de 37,5% para hipoglucemia nocturna, de los episodios de hipoglucemia nocturna, sin aumento en los niveles de HbA1c en comparación al grupo control en pacientes con DM1 usuarios de SAPT con la función LGS encendida(32).”
BackgroundThomas, A. (2018) · Diabetes aktuell · doi:10.1055/a-0805-2727 · Cited by 2
Pädiatrie – Motor der technologischen Weiterentwicklung in der Diabetologie
Biester, T., & Kordonouri, O. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0484-6 · Cited by 1
Treatment of Type 1 Diabetes Mellitus in Adults
Retnakaran, R. R., & Zinman, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00044-5 · Cited by 1
Tiselko, A. V., Yarmolinskaya, M. I., Borovik, N. V., Suslova, S. V., Владимировна, М. Е., & Milutina, Y. P. (2020) · Russian Bulletin of Obstetrician-Gynecologist · doi:10.17116/rosakush20202006156 · Cited by 1
Analysis: The Accuracy and Efficacy of the Dexcom G4 Platinum Continuous Glucose Monitoring System
van Beers, C. A. J., & DeVries, J. H. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815583508 · Cited by 1
“However, an effect on severe hypoglycemia has never been established in an randomized controlled trial evaluating the effect of conventional RT-CGM (without threshold suspension) on glycemic control.(7,8,24) Only 1 observational study showed a reduction in severe hypoglycemia.”
BackgroundL'insulinothérapie au xxie siècle : une symphonie de plus en plus harmonieuse
Benhamou, P., Hanaire, H. P., & Renard, É. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(21)00179-6 · Cited by 1
Ambler, G. R., Cameron, F. J., Joshi, K., & Wherrett, D. K. (2019) · Wiley eBooks · doi:10.1002/9781119152712.ch15 · Cited by 1
Romeo, G. R., Silva, P. S., & Cavallerano, J. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_294 · Cited by 1
Grassi, B. A., Caramés, B., Plaza‐Plaza, J. C., Onetto, M. T., Moreno, S., Sandoval, T., Tapia, N., Salas, F. M., & Revello, A. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108262 · Cited by 1
Wearable Artificial Pancreas Device Technology
Matsumoto, A. (2024) · Springer eBooks · doi:10.1007/978-981-99-8122-9_12 · Cited by 1
Сергеевич, Ш. А., Малых, О. Л., Габдрахмановна, Г. В., Михайловна, Ц. Т., Panov, V. G., Zhdanov, A., & Леонидович, Ш. П. (2023) · Vrach · doi:10.29296/25877305-2023-03-02 · Cited by 1
The History and Future of Diabetes Technology
Klonoff, D. C. (2019) · doi:10.2337/9781580406932.part1_ch01 · Cited by 1
Self-citationEarly Stages of Automated Insulin Delivery
Zisser, H., Hovorka, R., Basu, A., Battelino, T., Boughton, C. K., Breton, M. D., Buckingham, B. A., Brown, S. A., Cherñavvsky, D. R., Dassau, E., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251335685 · Cited by 2
“88 The Medtronic 670G was the first commercial hybrid AID pump approved for people over 14 years old in 2016, for children seven to 13 in 2018, and two to six years old in 2020.”
Self-citationReznik, Y., & Deberles, E. (2019) · Springer eBooks · doi:10.1007/978-3-319-98119-2_3 · Cited by 2
Artificial pancreas in pediatrics
Forlenza, G. P., Messer, L. H., Maahs, D. M., & Cherñavvsky, D. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00020-x · Cited by 1
Pickup, J. C. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_22-1 · Cited by 1
Gómez, A. M., Henao, D. C., Imitola, A., Múñoz, Ó., Rondón, M., Kattah, L., Guerrero, J. S., Morros, E., Llano, J. P., Jaramillo, M. G., et al. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.03.015 · Cited by 1
Blauw, H., & DeVries, J. H. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0196 · Cited by 1
In-Home Closed Loop Control for Artificial Pancreas: Patient and Provider Perspective
Ekhlaspour, L., & Maahs, D. M. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0432 · Cited by 1
Sandoval, D. A., Lamos, E. M., Younk, L. M., Hedrington, M. S., & Davis, S. N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.03833-2 · Cited by 1
Acute Complications of Diabetes
Hirsch, I. B., & Childs, B. P. (2017) · American Diabetes Association eBooks · doi:10.2337/9781580405690.ch09 · Cited by 1
Nanomedicine in Diabetes: Using Nanotechnology in Prevention and Management of Diabetes Mellitus
Savić, R., & Maysinger, D. (2014) · Wiley eBooks · doi:10.1002/9781118856017.ch11
Kontinuierliche Glucosemessung bei erwachsenen Typ-I-Diabetes-Patienten
Heinemann, L., & Siegmund, T. (2013) · Der Diabetologe · doi:10.1007/s11428-013-1121-4
The Dawn Phenomenon: Variability in Occurrence May Cause Need for Change in Treatment Strategy
Zimmerman, R. S. (2014) · Endocrine Practice · doi:10.4158/ep14364.co
Martín, A. A., Pascual, A. C., Gómez, F. J., Albarrán, O. G., Gil, A. L., Botella-Serrano, M., & Sánchez, L. F. P. (2015) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2015.04.003
A Perspective of Sensor-Augmented Insulin Pump Therapy in The Treatment of Type 1 Diabetes
Rayfield, E. J. (2014) · Endocrine Practice · doi:10.4158/ep14443.co
Le traitement par pompe à insuline externe
Puech-Bret, N., & Guillaume, E. (2014) · Soins · doi:10.1016/j.soin.2014.02.014
Grunberger, G., Abelseth, J. M., Bailey, T. S., Bode, B. W., Handelsman, Y., Hellman, R., Lane, W. S., Raskin, P., Tamborlane, W. V., & Rothermel, C. (2014)
Self-citationDIABETES E O FUTURO DO TRATAMENTO
Medina, J. L., Souto, S. B., & Ferreira, J. L. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.25756/rpf.v7i4.98 · Cited by 1
Dietary practices in treatment of Hypoglycaemia in elevated one-hour postload glucose and diabetes
Vindedzis, S. A. (2014) · eSpace (Curtin University)
Diabetische Notfallsituationen – die Hypoglykämie
Siegmund, T., & Schumm‐Draeger, P. (2014) · Der Diabetologe · doi:10.1007/s11428-014-1264-y
Siegmund, T. (2013) · Info Diabetologie · doi:10.1007/s15034-013-0468-3
Messsysteme für das kontinuierliche Glukosemonitoring – Vergleich der verschiedenen Systeme
Siegmund, T., Kolassa, R., & Thomas, A. (2014) · Diabetes aktuell · doi:10.1055/s-0034-1372222
The Hypoglycaemia-Hyperglycaemia Minimizer System in the Management of Type 1 Diabetes
Levy, B. L., McCann, T. W., & Finan, J. A. D. A. (2016) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2016.12.01.18
Prevention of Hypoglycemia Using the Predicted Low Glucose Suspend System
Chase, H. P. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0119
Tratamiento de la diabetes mellitus (III). Insulinoterapia
Carreras, G., & Pérez, A. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.012
9th Annual Symposium on Self-Monitoring of Blood Glucose, April 28–30, 2016, Madrid, Spain
Parkin, C. G., Homberg, A., & Hinzmann, R. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0336
Tauschmann, M., & Hovorka, R. (2016) · Springer eBooks · doi:10.1007/978-3-319-40242-0_14
Arbeitsmedizinische Aspekte bei Diabetes
Rinnert, K. (2017) · Zentralblatt für Arbeitsmedizin Arbeitsschutz und Ergonomie · doi:10.1007/s40664-017-0185-1
Ce que la mesure en continu du glucose apporte à la pompe à insuline
Hanaire, H. P. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30189-4
Closed Loop Systems In Type 1 Diabetes – A Dream That Might Soon Come True?
Guja, C. (2015) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2015-0014
“approach included 247 T1D subjects that were randomized to receive standard SAP therapy (126 patients, control group) or the low threshold suspend feature (121 patients, intervention group) for a total study period of 3 months [20].”
MethodAutomated Interruption of Insulin-Pump Therapy to Avoid Hypoglycemia
Brett, A. S. (2013) · Journal watch · doi:10.1056/nejm-jw.na31488
Regular Evaluation for Patients with Diabetes Mellitus
Koo, B. K. (2016) · Journal of Korean Diabetes · doi:10.4093/jkd.2016.17.4.238
Czupryniak, L., Myśliwiec, M., Jarosz-Chobot, P. A., Cypryk, K., Klupa, T., Szadkowska, A., Wierusz‐Wysocka, B., Strojek, K., & Walczak, M. (2014) · Via Medica Journals
Biester, T., & Wizemann, E. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-100389 · Cited by 1
“[61] Bergenstal RM, Klonoff DC, Garg SK et al.”
BackgroundSchoumacker-Ley, L., Duchesne, L., Cuny, T., Böhme, P., Benzirar, S., Fay, R., Ziegler, O., & Guerci, B. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30034-2
“(13) avait montré l’efficacité de la fonction suspension d’insuline en cas d’hypoglycémie, développée dans la pompe PARADIGM VEO.”
InfluentialKontinuierliche Glukosemessung (CGM) bei Erwachsenen
Gehr, B. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0203-0
Aristizábal, N., Ramírez, Á., Hincapié-García, J. A., Laiton, E., Aristizábal, C., Cuesta, D., Monsalve, C., Hincapié, G., Zapata, E., Abad, V., et al. (2015) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2015.11.006
Diabète de type1: pompeàinsuline
Renard, É. (2017) · doi:10.1016/b978-2-294-74646-8.00008-0
Wojtusciszyn, A. (2017) · doi:10.1016/b978-2-294-74646-8.00026-2
Herausforderungen des Diabetes an Jugendliche: Chancen und Grenzen neuer Technologien
Ziegler, R. (2017) · Diabetes aktuell · doi:10.1055/s-0043-115493
“[13] Bergenstal RM, Klonoff DC, Garg SK et al.”
BackgroundArbeitsmedizinische Aspekte bei Diabetes
Rinnert, K. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0165-7
Auf dem Weg zum Closed-Loop – Ziel und Realität
Biester, T., Danne, T., & Kordonouri, O. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-123111
Wizemann, E., & Biester, T. (2018) · Diabetes aktuell · doi:10.1055/a-0618-4826
Auf dem Weg zum Closed-Loop – Ziel und Realität
Biester, T., Danne, T., & Kordonouri, O. (2018) · Diabetes aktuell · doi:10.1055/a-0622-7858
Miljković, V. (2018) · Биомедицинска истраживања · doi:10.7251/bii1801037b
Prise en charge du diabète instable : approche humaine ou technologique ?
Benhamou, P. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30095-6
Technologische Innovationen in der Diabetes-Therapie
Strey, C. H. (2018) · Praxis · doi:10.1024/1661-8157/a003058
The impact of type 1 diabetes on the psycho-social well-being of adolescents
Spitz, M. (2017) · UpSpace Institutional Repository (University of Pretoria)
Progress in Device for Treatment of Diabetes
Nishimura, R. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.586
Advances in energy harvesting from heartbeat using flexible smart devices: state-of-the-art review
Zhang, Y., Lü, C., & Feng, X. (2018) · Scientia Sinica Informationis · doi:10.1360/n112018-00110
Strategies to mitigate hypoglycaemia in the artificial pancreas
Bondía, J., & Vehí, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00018-1
CGM-Parameter für das Diabetesmanagement – ein Update
Siegmund, T., Kolassa, R., & Thomas, A. (2019) · Diabetes aktuell · doi:10.1055/a-0918-0483
Hypoglykämien bei Diabetes mellitus: häufig und gefährlich
Holstein, A., & Holstein, D. J. F. (2019) · Diabetes aktuell · doi:10.1055/a-1031-2237
“[30] Bergenstal RM, Klonoff DC, Garg SK et al.”
BackgroundYamanouchi, L., Leong, W. B., Lloyd, J., Smith, A., Davies, P. H. O., & Basu, A. (2020) · Practical Diabetes · doi:10.1002/pdi.2264
Thérapeutique des désordres glycémiques
Monnier, L., & Colette, C. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00007-x
Bertachi, A. H. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Clinical Studies on Efficacy of Continuous Glucose Monitoring
Cherubini, V. (2020) · Springer eBooks · doi:10.1007/978-3-030-42806-8_4
Uduku, C. N., Reddy, M., & Oliver, N. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816714-4.00007-7
The dawn of automated insulin delivery: from promise to product
Nally, L. M., & Sherr, J. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816714-4.00016-8
Part II : Subcutaneous insulin infusion devices
Moorman, J. M. (2020) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1261
Nighttime Hypoglycemia in Children with Type 1 Diabetes after one Day of Football Tournament
Kamiński, M., Gawrecki, A., Araszkiewicz, A., Szadkowska, A., Skowrońska, B., Stankiewicz, W., Michalak, A., Cieluch, A., Dżygało, K., Seget, S., et al. (2020) · International Journal of Sports Medicine · doi:10.1055/a-1192-5992
Metadata
- Authors
- Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R.
- Affiliations
- Park Nicollet Health Services (US)
- Mills Peninsula Health Services (US)
- University of Colorado Denver (US)
- Atlanta Diabetes Associates (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 224-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102877966
- Cited by
- 652
- References
- 21
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 18 · 2023: 36 · 2022: 30 · 2021: 41 · 2020: 39 · 2019: 62 · 2018: 75 · 2017: 80 · 2016: 82 · 2015: 74 · 2014: 73 · 2013: 17
- FWCI
- 64.50
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Repositorio Institucional (Pontificia Universidad Javeriana) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- sensor-augmented pump, insulin pump therapy, nocturnal hypoglycemia, type 1 diabetes, HbA1c, hypoglycemia prevention, continuous glucose monitoring, glycemic control, hypoglycemic events, hypoglycemia severity, hypoglycemia duration
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Area Under Curve, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.